- In January 2025, The U.S. Food and Drug Administration (FDA) approved Suzetrigine (brand name Journavx) for the treatment of moderate to severe acute pain in adults. Suzetrigine is the first non-opioid pain medication in two decades to receive FDA approval, functioning as a selective NaV1.8 ion channel inhibitor, providing effective pain relief without the risks associated with opioids
- In January 2025, SanBio's SB623, a stem cell-based therapy for chronic motor deficits from TBI, showed promising Phase 2 clinical trial results. Patients receiving SB623 implants showed significant improvements in motor function. This positions SB623 as a potential game-changer for neuroregenerative treatments for TBI
- In December 2024, Pinteon Therapeutics' monoclonal antibody PNT001, targeting phosphorylated tau (pT231), progressed to Phase 1b trials. This novel approach aims to mitigate tau-related neurodegeneration following TBI and offers a potential treatment for cognitive impairments in TBI patients
- In October 2024, The University of California, San Francisco (UCSF) initiated a clinical trial to evaluate the efficacy of atorvastatin, candesartan, and minocycline for treating mild to moderate TBI. These drugs, shown to reduce brain inflammation in preclinical studies, are being tested for their potential to improve recovery from TBI
- In September 2024, AI algorithms and advanced imaging technologies are revolutionizing TBI diagnosis and treatment. AI is now being used to predict patient outcomes and personalize treatment plans, while quantitative imaging techniques are enhancing the precision of TBI assessments. These advancements are leading to more effective interventions and improved patient outcomes
